Explainer Outlines Eli Lilly Triple-Agonist Retatrutide for Weight Loss
US News summarizes what patients should know about the investigational GLP-1, GIP and glucagon receptor agonist.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 15 14:35 ETSource: US News Health
The wire
- 01US News Health published a consumer explainer on retatrutide, a triple-agonist weight-loss candidate.
- 02Retatrutide is among the most watched next-generation obesity drugs in development.
- 03Regulatory timing and final efficacy and safety data are not detailed in the source.
From the source
Read at news.google.comRetatrutide for Weight Loss: What to Know About the "Triple-Agonist" Drug